Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Diagnostik og behandling af maturity onset diabetes of the young type 3
Engelsk titel: Diagnosis and treatment of maturity onset diabetes of the young type 3 Läs online Författare: Rose, Kathrine ; Sidelmann Christensen, Alexander ; Storgaard, Heidi ; Haedersdal, Sofie ; Hansen, Torben ; Knop, Filip Krag ; Vilsböll, Tina Språk: Dan Antal referenser: 30 Dokumenttyp: Översikt UI-nummer: 18110005

Tidskrift

Ugeskrift for Laeger 2018;180(11)982-6 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.